January 25, 2019

January 25, 2019

This Country Singer’s Sore Throat Turned Out to Be a Sign of Cancer

Self Magazine – Jan. 24

Tonsil cancer is often lumped in with a group of cancers called oropharyngeal cancers, which are cancers of the throat, back of the tongue, and soft palate, Caitlin McMullen, M.D., a surgeon in the department of head and neck endocrine oncology at Moffitt Cancer Center, tells SELF. “In general these cancers are uncommon, but the rate of oropharyngeal cancers is rising worldwide, in particular in North America [in relation to] the human papillomavirus (HPV),” she says.

 

My farewell as Florida Trend publisher

Florida Trend – Jan. 25

We are blessed to have great hospitals (Moffitt, for example), modern treatments such as proton therapy, and researchers working hard to rid us of this disease. 

 

Moffitt Program Improves LGBTQ Health Care Education

Spectrum Bay News 9 – Jan. 23

Moffitt Cancer Center says its is leading the nation in addressing and improving LGBTQ health care concerns and education.

 

Sarasota Memorial starts work on cancer center

Sarasota Herald Tribune – Jan. 23

With the closest National Cancer Institute-designated hospital — Moffitt Cancer Center — more than an hour’s drive away in Tampa, the quest to develop a premier treatment program here reflects not only this region’s growth, but also an evolution in the practice and science of oncology. 

 

Molecular Cytogenetic Risk Stratification in ALL

OncLive – Jan. 22

Panelists: Mark R. Litzow, MD, The Mayo Clinic; Jae Park, MD, Memorial Sloan Kettering Cancer Center; Bijal Shah, MD H. Lee Moffitt Cancer Center & Research Institute; Anthony Stein Gehr Family Center for Leukemia Research

 

More About the Health and Needs of LGBTQ Patients With Cancer

Oncology Learning Network – Jan. 22

“Despite the overwhelming evidence of cancer disparities related to age, sex, race/ethnicity, income, social class, disability, and geographic location, there have been limited efforts to address cancer disparities by sexual orientation and gender identity (SOGI),” explained lead investigator Matthew B. Schabath, PhD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, and colleagues.

 

Oncologist Survey on Knowledge About LGBTQ Patients With Cancer

The ASCO Post – Jan. 22

Matthew B. Schabath, PhD, of the H. Lee Moffitt Cancer Center and Research Institute, is the corresponding author for the Journal of Clinical Oncology article.

 

Study: Oncologists Want More Education About LGBTQ Issues

Cancer.org – Jan. 22

The study was led by researchers from the NYU School of Medicine and Moffitt Cancer Center. It was published January 16, 2019 in the Journal of Clinical Oncology.

 

Revolutionizing the Treatment of Ph+ ALL with TKIs

OncLive – Jan. 22

Panelists: Mark R. Litzow, MD, The Mayo Clinic; Jae Park, MD, Memorial Sloan Kettering Cancer Center; Bijal Shah, MD H. Lee Moffitt Cancer Center & Research Institute; Anthony Stein Gehr Family Center for Leukemia Research

 

Age may dictate benefit of andecaliximab in gastric cancer

MD Edge – Jan. 22

A comprehensive view of precision oncology requires consideration not only of the tumor, but also of the microenvironment and the macroenvironment, agreed invited discussant Martine Extermann, MD, PhD, leader of the senior adult oncology program at the Moffitt Cancer Center in Tampa.

 

HPV test emerging as an alternative to the Pap smear

Tampa Bay Times – Jan. 22

In another recent twist, researchers at Moffitt Cancer Center in Tampa have developed a new test that can help guide cervical cancer screenings for women who test positive for HPV.

 

Editorial: Milestone in the long cancer fight

Tampa Bay Times – Jan. 21

Dr. Matthew Schabath, a cancer epidemiologist at Moffitt Cancer Center in Tampa, notes that people in the poorest geographic regions have higher rates of smoking, obesity, poor diets and are less likely to exercise. 

 

Dr. Strosberg Discusses Results for KEYNOTE-158

OncLive – Jan. 21

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab (Keytruda) in patients with advanced neuroendocrine tumors (NETs).

 

Doctor from Moffitt Cancer Center will discuss cancer prevention and treatment options

Villages News – Jan. 20

“Cancer Prevention, Screening and Treatment Options” will be presented at 6:30 p.m. Thursday, Jan. 24 at La Hacienda Recreation Center. Dr. Timothy Kubal, of the Moffitt Cancer Center, the top-ranked cancer hospital in Florida and the Southeast, will be the keynote speaker.

 

Cardio-Oncology: Matters of the Heart in Hematologic Cancers

Oncology Times – Jan. 20

Michael Fradley, MD, Director of the Cardio-Oncology Program and Associate Professor of Medicine in the Department of Cardiovascular Sciences at University of South Florida and Moffitt Cancer Center, co-chaired the 2018 Global Cardio-Oncology Summit in Tampa that attracted some 370 oncologists and cardiologists from 25 countries to explore all aspects cardio-oncology.

 

No Benefit Signal with Immunotherapy for NETs

MedPage Today -  Jan. 19

The safety profile of pembrolizumab was consistent with previously reported clinical experience with the drug, reported Jonathan Strosberg, MD, of Moffitt Cancer Center in Tampa, Florida, and colleagues.

 

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.